Chatham-Stephens Kevin, Taylor Ethel, Chang Arthur, Peterson Amy, Daniel Johnni, Martin Colleen, Deuster Patricia, Noe Rebecca, Kieszak Stephanie, Schier Josh, Klontz Karl, Lewis Lauren
EIS officer, 1600 Clifton Road NE MS C-09, Atlanta, GA.
Division of Environmental Hazards and Health Effects, National Center for Environmental Health, Centers for Disease Control and Prevention.
Drug Test Anal. 2017 Jan;9(1):68-74. doi: 10.1002/dta.2036. Epub 2016 Aug 4.
In September 2013, the Hawaii Department of Health (HDOH) was notified of seven adults who developed acute hepatitis after taking OxyELITE Pro™, a weight loss and sports dietary supplement. CDC assisted HDOH with their investigation, then conducted case-finding outside of Hawaii with FDA and the Department of Defense (DoD). We defined cases as acute hepatitis of unknown etiology that occurred from April 1, 2013, through December 5, 2013, following exposure to a weight loss or muscle-building dietary supplement, such as OxyELITE Pro™. We conducted case-finding through multiple sources, including data from poison centers (National Poison Data System [NPDS]) and FDA MedWatch. We identified 40 case-patients in 23 states and two military bases with acute hepatitis of unknown etiology and exposure to a weight loss or muscle building dietary supplement. Of 35 case-patients who reported their race, 15 (42.9%) reported white and 9 (25.7%) reported Asian. Commonly reported symptoms included jaundice, fatigue, and dark urine. Twenty-five (62.5%) case-patients reported taking OxyELITE Pro™. Of these 25 patients, 17 of 22 (77.3%) with available data were hospitalized and 1 received a liver transplant. NPDS and FDA MedWatch each captured seven (17.5%) case-patients. Improving the ability to search surveillance systems like NPDS and FDA MedWatch for individual and grouped dietary supplements, as well as coordinating case-finding with DoD, may benefit ongoing surveillance efforts and future outbreak responses involving adverse health effects from dietary supplements. This investigation highlights opportunities and challenges in using multiple sources to identify cases of suspected supplement associated adverse events. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.
2013年9月,夏威夷州卫生部(HDOH)收到通报,有7名成年人在服用减肥及运动膳食补充剂OxyELITE Pro™后患上急性肝炎。美国疾病控制与预防中心(CDC)协助HDOH开展调查,随后与美国食品药品监督管理局(FDA)及国防部(DoD)在夏威夷以外地区查找病例。我们将病例定义为2013年4月1日至12月5日期间,在接触减肥或增肌膳食补充剂(如OxyELITE Pro™)后出现的病因不明的急性肝炎。我们通过多种来源查找病例,包括来自中毒控制中心(国家中毒数据系统[NPDS])和FDA不良事件报告系统(MedWatch)的数据。我们在23个州和两个军事基地确定了40例病因不明的急性肝炎病例患者,他们均接触过减肥或增肌膳食补充剂。在35名报告了种族的病例患者中,15名(42.9%)报告为白人,9名(约25.7%)报告为亚洲人。常见症状包括黄疸、疲劳和深色尿液。25名(62.5%)病例患者报告服用过OxyELITE Pro™。在这25名患者中,22名有可用数据的患者中有17名(77.3%)住院治疗,1名接受了肝移植。NPDS和FDA MedWatch各发现了7名(17.5%)病例患者。提高在NPDS和FDA MedWatch等监测系统中搜索单个和分组膳食补充剂的能力,以及与国防部协调病例查找工作,可能有助于正在进行的监测工作以及未来涉及膳食补充剂对健康产生不良影响的疫情应对。本调查突出了利用多种来源识别疑似补充剂相关不良事件病例的机遇和挑战。2016年发表。本文为美国政府作品,在美国属于公共领域。